Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,

#3580 Sex differences in survival of neuroendocrine neoplasia in England 1995–2018

Introduction: Sex differences have been noted at different sites of Neuroendocrine Neoplasia in some registry studies internationally. Analysis of England's National Cancer Registry and Analysis Service (NCRAS) data can help to clarify the significance and importance of this.

Conference:

Presenting Author:

Authors: White B, Chandrakumaran K, Wong K, Rous B, Bouvier C,

Keywords: epidemiology, survival, sex, incidence,

#3544 Incidence, prevalence and survival of neuroendocrine neoplasia 1995–2018

Introduction: Incidence of neuroendocrine neoplasia (NEN) is rising worldwide. England's National Cancer Registry and Analysis Service (NCRAS) records more than 99.5% of tumors. Recent improvements to the registry allow NEN to be analysed with greater accuracy.

Conference:

Presenting Author: White B

Authors: White B, Chandrakumaran K, Wong K, Rous B, Bouvier C,

Keywords: epidemiology, incidence, prevalence, survival,

#3492 The first circulating tumor cell-derived explant (CDX) model of a Merkel cell carcinoma

Introduction: Poorly differentiated ExtraPulmonary NeuroEndocrine Carcinomas (EP-NECs) have a median overall survival of

Conference:

Presenting Author: Frizziero M

Authors: Frizziero M, Kilgour E, Simpson K, Rothwell D, Frese K,

Keywords: neuroendocrine carcinoma, Merkel cell carcinoma, circulating tumor cell, mouse model,